Healthcare Industry News: Tulip BioMed
News Release - September 26, 2006
Tulip BioMed Board Elects Two New Directors
Respected Industry Professionals Bring Expertise and Valuable Insight to Biotech Company's BoardSAN DIEGO, CA--(Healthcare Sales & Marketing Network)--Sep 26, 2006 -- Tulip BioMed, Inc. (Other OTC:TPBD.PK ), a developer of medical devices and patented technologies for use in the living tissue market, including plastic, cosmetic, and orthopedic surgeries, today announced its board of directors has elected two new directors, Jay Poe and Clifford Wright.
Jay Poe is president of Nypro Precision Assemblies, a multi-billion dollar medical device manufacturing company. Poe has more than 23 years of experience in injection molding, contract manufacturing and collaboration with industry-leading OEMs.
Clifford Wright has 19 years of engineering, technology, and management experience with emphasis on multidisciplinary system design and product development in the health sciences industry. Wright has more than 35 patents approved or pending. His technical expertise includes skills essential to successful product engineering and operations within the medical device industry.
Tulip BioMed's board of directors is now a board of five and continues to include founding directors, Marc Pilkington, John Wright and Darin Andersen. Pilkington will continue to serve as chairman of the board.
"We're fortunate to have Jay and Cliff on our board. Jay brings incredible medical device manufacturing expertise as well as experience working with leading OEMs. His advice will be invaluable as we move towards full scale production. Cliff will be a huge asset to the board as we address new markets and product development in the health sciences industry," said Tulip BioMed CEO Marc Pilkington. "I look forward to working with both as we bring our new disposable products to market across a wide range of applications worldwide."
About Tulip BioMed, Inc.
Tulip BioMed, Inc. (Other OTC:TPBD.PK ) is a Nevada corporation with operations based in San Diego, California. Founded in 2004, Tulip BioMed, Inc. is a medical device, biotechnology company that manufactures and distributes patented technologies for the plastic and cosmetic surgery, biopsy, orthopedic surgery, stem cell therapy and other living tissue markets. Tulip BioMed, Inc. is the exclusive licensee of patented syringe connection devices that use the worldwide recognized Tulip brand name. Tulip BioMed, Inc. manufactures, markets, and distributes medical devices, adapted with these and other patented technologies, to physicians, clinics, military, health organizations, hospitals and other distribution outlets. For more information go to: www.tulipbiomed.com. Products are available for sale at www.tulipdisposable.com.
Safe Harbor: This press release contains certain forward-looking information about Tulip BioMed, Inc., which is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Tulip BioMed, Inc., that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: our lack of operating revenue and earnings history, our need for additional capital to pursue our business strategy. We are a non-reporting company and as such do not make periodic filings with the Securities and Exchange Commission. We trade on the Pink Sheets and there can be no assurances that a liquid market will develop in our securities. Readers are cautioned not to place undue reliance on these forward-looking statements. Tulip BioMed, Inc. does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Source: Tulip BioMed
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!